CytomX Therapeutics, Inc.
- CTMX
- NASDAQ
- Biotechnology
- Oncology Immunotherapy
- Probody Platform
$2.34
Today +2.63%Quote Oct 19, 2026, 08:00 PM UTC
−15.22%over the last month
Max drawdown −24.1%From 1-month high −20.4%3 months −31.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About CytomX Therapeutics
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
69
Founded
2008
Market value
$509.9M
Quote Oct 19
Floor
$2.13
9.1% below price
Resistance
$2.35
0.6% above price
Price vs analyst targets
21 analysts
Lowest target
$6.00Highest target
$11.00
$6.00Highest target
$11.00
- Price $2.34
- Average target $8.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 263% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CTMXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free